Collectively, these data demonstrate that sunitinib improved TRAIL-induced apoptosis through enhanced JNK activation and that this may be a clinically actionable strategy to improve the anticancer activity of TRAIL in colon cancers. Here, TNFSF10 is linked to colonic neoplasm.